Cigna Flags Slowing GLP-1 Drug Trend, Shares Dip 2%
CI sits 20% above its 52-week low of $239.51.
Summary
Cigna's CFO disclosed on the Q2 earnings call that GLP-1 drug prescription growth is moderating, with coverage levels slightly declining and utilization growth trending down from prior elevated levels. This trend is expected to persist through year-end and is baked into the raised full-year outlook of at least $30.45 per share. The commentary adds a cautious note to an otherwise strong quarter where revenue and EPS beat consensus. Shares fell about 2%, reflecting concern that a slowdown in high-cost GLP-1 utilization could pressure pharmacy benefit revenue growth at Evernorth. The stock move is modest but the forward-looking signal on a key cost and revenue driver warrants attention.
At the time of this announcement, CI was trading at $288.42 on NYSE in the Life Sciences sector, with a market capitalization of approximately $76.3B. The 52-week trading range was $239.51 to $315.47. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.